Australia markets open in 9 hours 52 minutes

Aprea Therapeutics, Inc. (APRE)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
7.24+0.87 (+13.59%)
At close: 03:04PM EST
7.09 -0.15 (-2.07%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.37
Open6.47
Bid6.59 x 800
Ask7.50 x 1800
Day's range6.47 - 7.50
52-week range2.78 - 7.71
Volume18,784
Avg. volume14,400
Market cap27.053M
Beta (5Y monthly)N/A
PE ratio (TTM)0.59
EPS (TTM)12.31
Earnings date28 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

    DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to initiate clinical trials of APR-1051. APR-1051 is an oral inhibitor of WEE1 kinase, which plays important role in cell cycle regulation and DNA da

  • GlobeNewswire

    Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

    DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will deliver a presentation at the 7th DDR Inhibitors Summit, to take place January 30 to February 1, 2024 in Boston, MA. “We are excited to have the opportunity to present at the DDR Inhibitors Summit,” said Dr. Oren Gila

  • Simply Wall St.

    Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...